A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel on Ablation of Upper Urinary Tract Urothelial Carcinoma

Trial Profile

A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel on Ablation of Upper Urinary Tract Urothelial Carcinoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs Mitomycin (Primary)
  • Indications Urogenital cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms OLYMPUS
  • Sponsors UroGen Pharma
  • Most Recent Events

    • 03 Apr 2018 According to an UroGen Pharma media release, interim analysis for this study will be presented, in an oral presentation, at the 113th American Urological Association's (AUA) Annual Meeting 2018.
    • 15 Mar 2018 According to an UroGen Pharma media release, the top-line data from this study are expected in Q3 2018 and assuming positive results the company have planned submission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in Q1 2019.
    • 15 Mar 2018 According to an UroGen Pharma media release, the company will present an interim analysis from this pivotal trial at an upcoming medical meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top